Table 2.
KEGG analysis of top ten enrichment score (−log10(P value)) values of the significant enrichment pathway.
| Pathway ID | Definition | Fisher's P value | Enrichment score | Genes |
|---|---|---|---|---|
| Hypomethylated diabetes versus control | ||||
| hsa05143 | African trypanosomiasis | 0.0073 | 2.133882 | F2RL1//HPR//THOP1 |
| hsa05340 | Primary immunodeficiency | 0.0086 | 2.064522 | AIRE//CD8A//IGLL1 |
| hsa04640 | Hematopoietic cell lineage | 0.0200 | 1.697467 | CD1B//CD5//CD8A//CD9 |
| hsa04970 | Salivary secretion, Homo sapiens | 0.0216 | 1.665411 | ADRB2//CST5//KCNN4//NOS1 |
| hsa00670 | One carbon pool by folate | 0.0229 | 1.639815 | ATIC//MTFMT |
| hsa04977 | Vitamin digestion and absorption | 0.0322 | 1.490856 | SLC19A2//SLC23A1 |
|
| ||||
| Hypermethylated diabetes versus control | ||||
| hsa00910 | Nitrogen metabolism | 0.0015 | 2.818773 | CA13//CA5B//CA9//CPS1//GLU |
| D2 | ||||
| APLN//CHRNA1//CHRNA5//CH | ||||
| RNB3//CNR1//EDN1//EDNRB// | ||||
| FSHB//GABRA6//GABRG2//GA | ||||
| BRR1//GCG//GHR//GPR156//G | ||||
| RIA1//GRM4//HCRTR2//LGR4// | ||||
| NMUR2//NPFF//NPY1R//P2RX6 | ||||
| hsa04080 | Neuroactive ligand-receptor interaction | 0.0207 | 1.683002 | //P2RY14//PLG//RXFP1//TAC4 |
| hsa00524 | Butirosin and neomycin biosynthesis | 0.0254 | 1.594577 | GCK//HK2 |
| Glycosaminoglycan biosynthesis, heparan | EXT1//EXTL2//HS3ST5//XYLT | |||
| hsa00534 | Sulfate/heparin | 0.0361 | 1.441751 | 1 |
| CACNB2//EDN1//IGF1//ITGA1// | ||||
| ITGB1//MYH6//PRKAG2//PRK | ||||
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 0.0362 | 1.441099 | AG3//TPM1 |
| hsa00750 | Vitamin B6 metabolism | 0.0368 | 1.433896 | PDXP//PSAT1 |
| hsa04950 | Maturity onset diabetes of the young | 0.0413 | 1.384024 | GCK//HNF1A//NR5A2//PDX1 |
|
| ||||
| Hypomethylated diabetes versus prediabetes | ||||
| hsa00770 | Pantothenate and CoA biosynthesis | 0.0137 | 1.86211 | COASY//PANK2 |
| hsa04640 | Hematopoietic cell lineage | 0.0141 | 1.850323 | CD14//CD1A//CD1B//CD3E |
| hsa00590 | Arachidonic acid metabolism | 0.0304 | 1.516647 | CYP2E1//GGT1//PLA2G12A |
| hsa03320 | PPAR signaling pathway | 0.0369 | 1.433374 | ACSL4//NR1H3//PCK2 |
| hsa00591 | Linoleic acid metabolism | 0.0378 | 1.42268 | CYP2E1//PLA2G12A |
|
| ||||
| Hypermethylated diabetes versus prediabetes | ||||
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 0.0063 | 2.201901 | CACNA1S//DMD//ITGA4//MY |
| H6//PRKAB2//PRKAG3//TGFB3 | ||||
| //TNF//TNNI3//TPM4 | ||||
| ACVR1B//CCR6//CCR8//CX3C | ||||
| R1//CXCL1//CXCL9//EDAR//G | ||||
| HR//IFNA2//IFNA21//IL18RAP// | ||||
| IL3//IL3RA//IL4R//IL9//TGFB3// | ||||
| TNF//TNFRSF10D//TNFRSF14// | ||||
| hsa04060 | Cytokine-cytokine receptor interaction | 0.0085 | 2.071022 | TNFRSF9//TNFSF18//TNFSF8 |
| hsa03060 | Protein export | 0.0210 | 1.678045 | SEC61G//SRP9//SRPR//SRPRB |
| ADCY4//CACNA1S//DMD//ITG | ||||
| A4//MYH6//TGFB3//TNF//TNNI | ||||
| hsa05414 | Dilated cardiomyopathy | 0.0251 | 1.600573 | 3//TPM4 |
| ADCY4//ANAPC11//ATF1//ATF | ||||
| 3//CCNB2//CREM//HLA- | ||||
| A//HLA- | ||||
| E//IKBKB//KRAS//MAD2L1//M | ||||
| RAS//MSX2//NFYB//TGFB3//T | ||||
| hsa05166 | HTLV-I infection | 0.0382 | 1.418455 | LN2//TNF//WNT16//WNT5B |
| ACSL6//IKBKB//PRKAB2//PRK | ||||
| hsa04920 | Adipocytokine signaling pathway | 0.0455 | 1.342336 | AG3//PTPN11//SOCS3//TNF |
|
| ||||
| Hypomethylated prediabetes versus control | ||||
| hsa00590 | Arachidonic acid metabolism | 0.0026 | 2.593265 | CYP4F3//CYP4F8//PLA2G2C//P |
| LA2G4E | ||||
| hsa00592 | Alpha-linolenic acid metabolism | 0.0211 | 1.676649 | PLA2G2C//PLA2G4E |
| hsa00591 | Linoleic acid metabolism | 0.0278 | 1.555232 | PLA2G2C//PLA2G4E |
| MYLK3//PLA2G2C//PLA2G4E// | ||||
| hsa04270 | Vascular smooth muscle contraction | 0.0301 | 1.521206 | RAMP3 |
| hsa04350 | TGF-beta signaling pathway | 0.0352 | 1.453226 | LEFTY2//SP1//TGFB3 |
|
| ||||
| Hypermethylated prediabetes versus control | ||||
| hsa05202 | Transcriptional misregulation in cancer | 0.0190 | 1.720526 | CCNT1//ELK4//EYA1//RARA |
| hsa05221 | Acute myeloid leukemia | 0.0425 | 1.371986 | CHUK//RARA |